CLLSCellectis S.A.vs its industry peers
A metric-by-metric comparison of Cellectis S.A. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CLLSEsta | — | — | — | — | 75.8%#4 | -83.9%#12 | -45.3%#3 | -89.1%#4 | — | — | 26.0%#7 | — |
| ARGX | $65.3B#1 | — | — | 1838.4x#4 | 254.4%#2 | 55.1%#3 | 2965.7%#1 | — | — | — | 46.1%#6 | — |
| ATTO | $1.1B#4 | — | — | — | — | — | — | — | — | — | 340.9%#1 | — |
| AUTL | $595M#5 | — | 7.9x#2 | 7.9x#2 | 644.9%#1 | -30.3%#11 | -358.9%#6 | -384.2%#7 | — | — | 55.2%#4 | — |
| BNTX | $26.1B#2 | — | — | — | — | — | — | — | — | — | 3.5%#8 | — |
| CGEN | $248M#6 | 6.9x#2 | 2.4x#1 | 3.4x#1 | 161.1%#3 | 348.4%#1 | 43.1%#2 | 34.4%#2 | — | — | 84.9%#3 | — |
| CKDXF | — | — | — | — | -80.0%#9 | 26.1%#5 | -623048.0%#10 | — | — | — | — | — |
| CLDWW | — | — | — | — | — | 10.1%#8 | -44977.8%#9 | -635.4%#8 | — | — | — | — |
| CPMV | — | — | — | — | — | 25.4%#7 | — | — | — | — | — | — |
| CRDL | $217M#7 | — | — | — | — | — | — | — | — | — | 96.4%#2 | — |
| CYVNY | — | — | — | — | -80.0%#9 | 26.1%#5 | -623048.0%#10 | — | — | — | — | — |
| DBVT | $4.0B#3 | — | 25.2x#3 | 716.0x#3 | 35.8%#5 | -29.0%#9 | -2609.2%#7 | -91.6%#5 | — | — | 48.2%#5 | — |
| DBVTF | — | — | — | — | 35.8%#5 | -29.0%#9 | -2609.2%#7 | -91.6%#5 | — | — | — | — |
| DNABW | — | — | — | — | -25.1%#8 | 42.8%#4 | -185.3%#4 | -0.1%#3 | — | — | — | — |
| ELUT | — | 0.9x#1 | — | — | -15.0%#7 | 198.9%#2 | -218.9%#5 | 339.0%#1 | -122.6%#1 | — | -57.0%#9 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice